Conclusion: The MPAD value measured at the initial admission of COVID-19 patients hospitalized in the intensive care unit is not a parameter that can be used to predict mortality.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim: The aim of this study was to examine the effect of main pulmonary artery diameter (MPAD), which is evaluated in patients when first admitted to the intensive care unit due to COVID-19, on mortality.
📊
Key Findings & Data:Material and Method: Thoracic computed tomography examinations performed during the initial admission to hospital of patients who were treated in the intensive care unit between October 1, 2020, and June 1, 2021, were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: The MPAD value measured at the initial admission of COVID-19 patients hospitalized in the intensive care unit is not a parameter that can be used to predict mortality.
🔬Design:Modeling & Simulation
📍Scope:2020 Verileri
⚙️Variables:COVID-19 · main pulmonary artery diameter · intensive care unit
Abstract
Aim: The aim of this study was to examine the effect of main pulmonary artery diameter (MPAD), which is evaluated in patients when first admitted to the intensive care unit due to COVID-19, on mortality. Material and Method: Thoracic computed tomography examinations performed during the initial admission to hospital of patients who were treated in the intensive care unit between October 1, 2020, and June 1, 2021, were evaluated retrospectively. Cox regression analysis was performed with the program R-Project to evaluate the relationship between MPAD and mortality. Results: No significant correlation was found between MPAD and mortality in models used with or without adjusting for age and sex (respectively P: 0.890 and P: 0.920). Conclusion: The MPAD value measured at the initial admission of COVID-19 patients hospitalized in the intensive care unit is not a parameter that can be used to predict mortality.
ÇORAPLI, G., ÇİL, E., TUTAK, A. Ş., ÇORAPLI, M. (2022). The effect of main pulmonary artery diameter on the prognosis of COVID-19 patients in the ICU. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 3, 778–781. https://ajindex.com/articles/776545
Çil B, Kabak M. Comparative evaluation of tocilizumab versus high dose methylprednisolonetherapy in mild acute respiratory distress syndrome related to COVID-19 pneumonia: a retrospective cohort study. New Trend Med Sci 2021; 2: 130-5.
Hui DS, Azhar EI, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91: 264-6.
Sohrabi C, Alsafi Z, O'neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71-6.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents 2020; 56: 106054. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41: 3038-44.
Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. Turk Kardiyoloji Dernegi Arsivi 2014; 42: 55-66.
Douschan P, Kovacs G, Avian A, et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 2018; 197: 509-16.
Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5-12.
Nazzareno G, Marc H, Jean LV, Simon G, Irene L, Adam T. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016; 37: 67-119.
Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GR, Presberg KW. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 1998; 113: 1250-6. Republic of Turkey Ministry of Healhty, Adult patient treatment in COVID-19, December 2021.https://covid19.saglik.gov.tr/Eklenti/42169/0/covid19rehberieriskinhastayonetimivetedavi20122021v6pdf.pdf. (Accessed February 10,2022).
Truong QA, Massaro JM, Rogers IS, et al. Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomographyclinical perspective: The Framingham Heart Study. Circ Cardiovasc Imaging 2012; 5: 147-54.